T

Thermo Fisher Scientific

Makes lab instruments, reagents and supplies

Team Leader - Packaging

Full-Time
No salary listed
Mid, Senior
Bachelor's, Master's
Allentown, PA, USA
In Person
Manufacturing & Production OperationsMachine & Process Operation
No H1B Sponsorship

About the job

Requirements
  • Must be legally authorized to work in the United States without sponsorship.
  • Must pass a comprehensive background check, including drug screening.
  • An advanced degree with three years of experience, or a bachelor's degree with five years of experience, in pharmaceutical packaging or an FDA-regulated industry is required.
  • Preferred fields of study include Business, Management, Engineering, a scientific field, or a related discipline.
  • Three or more years of supervisory experience is preferred.
  • Lean or Six Sigma Green Belt or Black Belt certification is preferred.
  • Candidates with six or more years of progressively responsible and relevant work experience may be considered, including three years of supervisory experience and experience in pharmaceutical packaging, the pharmaceutical industry, or an FDA-regulated industry.
  • Strong role-model leadership skills are required.
  • Well-developed written and verbal communication and interpersonal skills are required.
  • Sound judgment and decision-making skills are required.
  • Analytical thinking and problem-solving skills are required.
  • Knowledge of continuous improvement, Lean Manufacturing, and/or Six Sigma is required.
  • Experience in all aspects of the packaging process is required.
  • Experience implementing Lean Manufacturing techniques, including line balancing, Takt Time, 5S, SMED, and TPM, is required.
  • Clinical or pharmaceutical packaging experience is preferred.
  • An industrial engineering background or training is preferred.
  • Experience leading teams of more than 10 employees is required.
  • A certification in manufacturing, management, or pharmaceuticals is preferred.
  • Project Management Professional certification or project management experience is preferred.
  • Ability to read, understand, and follow standard operating procedures and policies in a Good Manufacturing Practice environment is required.
  • Ability to manage personnel in a current Good Manufacturing Practice environment is required.
  • Must be able to stand continuously, walk frequently, sit as required, and frequently lift or carry up to 50 pounds.
  • Must be able to bend frequently, squat as required, reach above shoulder level, and perform repetitive actions, grasping, pushing, pulling, and fine manipulation with both hands.
  • Must be able to perform occasional repetitive actions with both feet.
  • Must meet visual requirements for close and distance vision, color vision, peripheral vision, depth perception, and focus adjustment.
  • Must meet applicable visual acuity and color-vision standards for inspection of pharmaceutical products, components, and labels in a current Good Manufacturing Practice environment.
  • Personal Protective Equipment certification, including for filtering face masks, PAPR, N-95 masks, half-face masks, and safety glasses, is required.
  • Must be able to work in both hot and cold environments.
Responsibilities
  • Oversee 20–25 employees working on multiple production lines in a clinical pharmaceutical manufacturing and packaging environment.
  • Apply Good Manufacturing Principles in all areas of responsibility.
  • Coach and mentor employees, and communicate with them professionally and accessibly.
  • Serve as the technical subject matter expert for each process within the area and communicate process information to internal and external stakeholders.
  • Identify problems and improvement opportunities proactively and independently, implement solutions, and prevent recurrence.
  • Measure team, individual, and process performance; set goals and hold the team and individuals accountable.
  • Foster employee education and personal development by providing opportunities for growth and exposure, and training and motivating the workforce.
  • Demonstrate and promote the company's vision of Integrity, Intensity, Innovation, and Involvement.
  • Conduct activities safely and efficiently.
  • Direct, lead, supervise, and support personnel; coach, listen to, and advise employees.
  • Learn and understand packaging processes; investigate process deviations, identify root causes, and implement corrective actions.
  • Communicate and train employees on their duties, responsibilities, and company policies and procedures.
  • Lead continuous process improvements, eliminate waste, increase effectiveness, and maximize operational efficiency while improving safety, quality, delivery, and cost.
  • Oversee daily scheduling of packaging operations and provide work direction across multiple production areas.
  • Ensure employees work safely and comply with internal and external regulations, procedures, and standards.
  • Identify, measure, and improve critical metrics; communicate performance expectations and hold employees accountable through the Performance Management and Development process.
  • Consistently apply company and site policies and procedures.
  • Ensure standard operating procedures are current and accurately reflect packaging-floor operations, and ensure technicians understand and follow them.
  • Develop employee career-path plans to support growth and fulfillment, and motivate employees to achieve work goals.
  • Serve as a role model leader.
  • Work primarily in a production environment, standing for extended periods to monitor room activities and assist with production requirements as needed.
  • Perform other duties as assigned to meet business needs.
Desired Qualifications
  • Lean or Six Sigma Green Belt or Black Belt certification.
  • Clinical or pharmaceutical packaging experience.
  • A certification in manufacturing, management, or pharmaceuticals.
  • Project Management Professional certification or project management experience.

About the company

T

Thermo Fisher Scientific

View

Thermo Fisher Scientific makes and sells the instruments, chemicals, consumables and lab services that drug companies, hospitals, universities and industrial labs use for research, testing and production. Its products cover work from gene sequencing and protein analysis to diagnostic tests and lab freezers, and its distribution arm ships supplies to labs worldwide. Drug developers also hire it to run clinical trials and to manufacture medicines under contract. It earns money from consumables that labs buy again and again, along with instrument sales, service contracts and outsourcing fees. The company traces its roots to Thermo Electron, founded in 1956, which merged with Fisher Scientific in 2006, and it is based in Waltham, Massachusetts.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Drugmaker demand is firming: revenue rose 10% to $11.99 billion in the June 2026 quarter, 5% excluding deals and currency.
  • Profits are outpacing sales, which supports stock grants: adjusted earnings per share rose 13% in the June 2026 quarter.
  • Career paths span many businesses: Thermo Fisher runs four segments, from diagnostics to contract drug development.

What critics are saying

  • Factory jobs are shrinking: Thermo Fisher announced in January 2026 it will close its Asheville plant, cutting 421 jobs.
  • Whole units get sold: microbiology, with $645 million in 2025 sales, went to buyout firm Astorg in August 2026.
  • Cuts reach California too: Thermo Fisher filed in January 2026 to lay off 173 Carlsbad workers by March.

What makes Thermo Fisher Scientific unique

  • Many familiar lab brands sit under one roof: Thermo Fisher owns Thermo Scientific, Applied Biosystems, Invitrogen and Fisher Scientific.
  • Thermo Fisher reaches labs through its own sales force of about 14,000 people, per its 2025 annual filing.
  • Its trial-data unit Clario has supported about 70% of FDA and EMA novel drug approvals over the past decade.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • 401(k) Retirement Plan
  • 401(k) Company Match

Company News

CemNet
Oct 15th, 2026
Thermo Fisher launches automated XRD system.

Thermo Fisher launches automated XRD system. Published 15 October 2026, 08:33 Get daily news, weekly insights and market analysis in your inbox. Thermo Fisher Scientific has introduced the ARL X'TRA Pro X-ray diffractometer for automated mineralogical analysis in cement and mining laboratories. The system is designed for unattended operation, with capacity for up to 98 samples. According to the company, throughput ranges from 50 to more than 100 samples per day, depending on analytical requirements. Its X-ray source is rated at up to 3kW. For cement producers, X-ray diffraction supports the identification and quantification of mineral phases in raw materials, clinker and finished cement. Automated sample handling can help laboratories maintain routine analysis while reducing manual intervention. TOPICS IN THIS ARTICLE

Business Wire
Oct 6th, 2026
Thermo Fisher unveils OSD Express and expands drug development capabilities at CPHI Milan 2026

Thermo Fisher Scientific is showcasing expanded drug development and manufacturing capabilities at CPHI Milan 2026, running 6-8 October. The company is introducing OSD Express for oral solid dose development and expanding small molecule capabilities through collaboration with AustinPx, which provides access to KinetiSol Technology for improving drug bioavailability. The firm is investing in tableting, laboratory and packaging facilities across France, Canada and North America. For sterile products, new Steriles Express Solutions aim to deliver Phase I or II clinical trial material in 20 weeks. Thermo Fisher is also expanding bioprocessing capacity and clinical trial supply infrastructure, including a 52,000-square-foot facility in New York. The company is deploying generative AI to reduce master informed consent form drafting time by 50%. Thermo Fisher generates over $45 billion in annual revenue.

BioPharma Watch
Oct 6th, 2026
Thermo Fisher Scientific showcases new solutions and expanded capabilities to accelerate Drug Development at CPHI Milan 2026.

Thermo Fisher Scientific showcases new solutions and expanded capabilities to accelerate Drug Development at CPHI Milan 2026. Key Takeaway: Thermo Fisher Scientific is set to showcase its expanded drug development and manufacturing capabilities at CPHI Milan 2026. The company aims to assist pharmaceutical and biotechnology firms in navigating complex commercialization processes. Among its new offerings is OSD Express, designed to enhance predictability in drug development. Market sentiment analysis. Positive factors. * Thermo Fisher Scientific is expanding its drug development capabilities. * New solutions aim to help companies navigate commercialization paths. * Showcasing innovations at a major industry event enhances visibility. New development solutions, expanded global capacity, and advanced digital technologies help pharma and biotech companies reduce complexity and scale toward commercialization Key facts. - New solutions for drug product development:New OSD Express and Steriles Express Solutions provide defined development approaches designed to increase predictability and help programs advance more efficiently, while Accelerator(TM) Drug Development connects capabilities across development to reduce handoffs and maintain continuity. - Expanded capabilities and capacity:Investments across oral solid dose, sterile drug product, biologics, and clinical supply are expanding development and manufacturing capabilities globally, including new small molecule technologies through Thermo Fisher's collaboration with AustinPx. - Technology delivering measurable impact:AI, data, and digital technologies are being applied across clinical development, including generative AI applications that reduced master informed consent form draft time by 50% and, in some studies, reduced CRA site enrollment and activation activities by 15-30%. MILAN-(BUSINESS WIRE)-Thermo Fisher Scientific, the world leader in serving science, is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotechnology companies navigate increasingly complex paths to commercialization, reduce friction, and maintain momentum. The company will showcase these new and expanded capabilities at CPHI Milan 2026, Oct. 6-8. Among the new offerings isOSD Express, a defined solution designed to increase predictability and advance oral solid dose development more efficiently. The offering reflects the broader approach ofAccelerator(TM) Drug Development, which connects scientific expertise and capabilities across drug development, clinical trials, endpoint solutions, clinical supply, and laboratory services to reduce handoffs and help customers maintain continuity as programs advance. Additionally, Thermo Fisher is expanding small molecule capabilities through its collaboration withAustinPx, giving customers access to KinetiSol(TM) Technology, a solvent-free technology designed to improve the bioavailability of poorly soluble drugs and support development and scale-up through commercial manufacturing. Targeted investments in tableting, laboratory, and packaging capabilities are also expanding oral solid dose development and commercial manufacturing, including new Gerteis technology for advanced dry granulation and improved tablet manufacturing efficiency in Bourgoin, France, and Whitby, Canada, and serialized packaging capabilities in Cincinnati and Toronto. For sterile drug product programs,Steriles Express Solutionsprovide a defined approach for early development and late-stage technology transfer. Steriles Express Early Development is designed to provide Phase I or II clinical trial material in as little as 20 weeks, while Steriles Express Tech Transfer can provide a Phase III GMP batch in as little as 26 weeks.* Supporting these pathways are continued investments in sterile drug product capacity, including new and expanded lines in Plainville, Massachusetts; Monza, Italy; and Ferentino, Italy, for development and commercial manufacturing of vials and prefilled syringes. Thermo Fisher is also expanding fill-finish and drug-device capabilities in Ridgefield, New Jersey, including through its previously announcedcollaboration with SHL Medical. "Drug development increasingly depends on decisions and capabilities that span traditional boundaries, from development and manufacturing to clinical supply and clinical execution," said Mike Shafer, Executive Vice President and President, Biopharma Services, Thermo Fisher Scientific. "We're investing not only in capacity, but in how those capabilities connect. That gives our customers greater continuity as they navigate critical transitions, scale their programs, and prepare for commercialization." Strengthening capabilities across the development pathway. Beyond drug product, Thermo Fisher continues to invest in capabilities across biologics development, manufacturing, and clinical supply. New bioprocessing equipment in Plainville will expand U.S.-based cGMP monoclonal antibody manufacturing capacity, while the recently openedU.S. Bioprocess Design Centerhelps customers translate process innovations into scalable solutions for biologics development and manufacturing. Thermo Fisher has also expanded its Gibco(TM) cell culture media portfolio withCHO-K1 Catalog Panel Media and Feed, a cGMP-ready portfolio designed to support cell growth and protein production. In clinical trial supply, a 52,000-square-foot expansion in Bohemia, New York, will increase clinical label manufacturing capacity, while a new facility in Heiwajima, Tokyo, is expected to approximately double Japan's storage, distribution and secondary packaging capacity, ranging from controlled ambient to ultra-low temperature. Across the global clinical supply network, Thermo Fisher is also making significant investments in technologies supporting drug-device combination product assembly, labeling and packaging. These scalable technologies enable fit-for-phase automation, supporting programs from early clinical development through commercialization as volume and complexity increase. Applying digital technologies and data to improve development execution. Thermo Fisher is applying AI, data, and digital technologies to improve execution and support more informed decisions across clinical development. Within the PPD(TM) clinical research business, generative AI is being used to accelerate clinical development activities, including a50% aggregate reductionin master informed consent form draft time. Thermo Fisher is also expanding evidence-generation capabilities through thePPD(TM) CorEvitas(TM) Vitiligo Registry, designed to generate longitudinal real-world evidence on treatment effectiveness, disease burden, and patient outcomes. In digital clinical solutions,Clario's eCOA Swiftcaptures patient-reported data in early-stage oncology trials to help sponsors better understand tolerability and patient impact as programs advance. Thermo Fisher experts share insights at CPHI Milan. These shifts in how drug development is executed, from the role of strategic partnerships to the practical application of AI, will also be explored by Thermo Fisher experts at CPHI Milan: CDMO Consolidation: Strategic Partnerships or Dangerous Dependencies?- Hannah Spaepen, Senior Director, CMC Portfolio Management, Pharma Services, will participate as a panelist Tuesday, Oct. 6, from 11:35 a.m. - 12:20 p.m. CET. Putting AI to work in drug development: Practical applications that deliver measurable value- Anil Kane, Global Head of Technical and Scientific Affairs, Pharma Services, will present Wednesday, Oct. 7, from 1:45 - 2:10 p.m. CET. To learn more about these and other developments, visit Thermo Fisher Scientific atbooth 6A2, where specialists in drug development, manufacturing, and clinical services will be available throughout the conference to discuss customer needs and challenges. * Actual Steriles Express timelines may vary based on defined program parameters and scope. About Thermo Fisher Scientific. Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Its Mission is to enable its customers to make the world healthier, cleaner and safer. Whether its customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics, or the development and manufacture of life-changing therapies, BiopharmaWatch is here to support them. Its global team delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through its industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. For more information, please visit www.thermofisher.com. Frequently asked questions. What is Thermo Fisher showcasing at CPHI Milan 2026? Thermo Fisher is showcasing its expanded drug development and manufacturing capabilities. What is OSD Express? OSD Express is a new solution designed to increase predictability in drug development. When is CPHI Milan 2026 taking place? CPHI Milan 2026 will be held from October 6 to 8. Who does Thermo Fisher aim to assist? Thermo Fisher aims to assist pharmaceutical and biotechnology companies.

Yahoo Finance
Sep 28th, 2026
Thermo Fisher Scientific to resell Evosep Eno separation platform for proteomics workflows

Evosep has entered a reseller agreement with Thermo Fisher Scientific for its Evosep Eno separation platform. Through the partnership, Thermo Fisher Scientific will offer the platform as part of its mass spectrometry solutions portfolio, combining its global reach with Evosep's separation technology. The Evosep Eno platform addresses the need for standardised proteomics in research, drug discovery, and clinical applications. It delivers robustness, ease of use, and throughput whilst minimising operational complexity. Customers will be able to purchase Evosep Eno directly through Thermo Fisher Scientific. The platform enables standardised separations across laboratories, instruments, and operators, supporting reproducible results for large-scale studies. The agreement supports applications including population studies, biomarker discovery, drug development, and clinical proteomics initiatives.

Contract Pharma
Sep 28th, 2026
Thermo Fisher launches Nicolet RaptIR X FTIR Microscope.

Thermo Fisher launches Nicolet RaptIR X FTIR Microscope. New microscopy platform combines high-resolution imaging and FTIR spectroscopy to accelerate materials, pharmaceutical and microplastics analysis. September 28, 2026 Associate Editor, Contract Pharma Thermo Fisher Scientific has introduced the Thermo Scientific Nicolet RaptIR X FTIR Microscope, a new Fourier Transform Infrared (FTIR) microscopy platform aimed at making advanced chemical analysis faster, more accessible and easier to perform across a broad range of laboratory applications. The new system combines high-definition optical microscopy with FTIR microspectroscopy, enabling scientists to visualize microscopic features and determine their molecular composition in a single workflow. According to Thermo Fisher, the RaptIR X microscope builds on five decades of Nicolet FTIR innovation and is engineered to simplify FTIR microscopy for both experienced spectroscopists and newcomers. The instrument is operated through the company's OMNIC Paradigm software, which provides guided workflows for sample acquisition and analysis intended to accelerate the path from measurement to results. "The RaptIR X microscope brings the speed, precision and flexibility laboratories need to investigate increasingly complex samples, while making advanced FTIR microscopy easier to use than ever before," said Ganesh Prasad, general manager of Vibrational Spectroscopy Products at Thermo Fisher Scientific. "It's a platform that reflects our commitment to innovation, giving laboratories the confidence to move from a microscopic observation to a molecular answer, quickly and reliably." Among the system's key performance features, the company highlighted the ability to collect up to 10 spectra per second at 5-micron spatial resolution for rapid chemical mapping. The microscope also delivers 1-micron visible resolution and 5-micron infrared resolution, helping users identify and characterize microscopic features with high precision. Additional capabilities include a heavy-duty stage that can accommodate samples up to 40 mm thick and weighing as much as 5 kg, automated detector switching for reproducible measurements, and a modular architecture that can operate as a standalone system or integrate with Nicolet Apex and Nicolet iS50 FTIR spectrometers. Optional enhancements such as micro-ATR, fluorescence visualization, near-infrared microscopy and polarized analysis allow laboratories to expand the platform as analytical requirements evolve. Add us as a preferred source on Google. Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.